"We're proud to provide families with a generic option of this important medication," said Jon Holden, Senior Vice President and General Manager, Generics at Endo. "Glycopyrrolate oral solution joins our extensive portfolio of high-quality, lower-cost generic products—and our reputation for dependable quality is an especially essential factor when treating children."

According to IQVIA^™, CUVPOSA^® sales were approximately $27 million for the 12 months ended October 31, 2021.

CUVPOSA^® is a registered trademark of Merz Pharmaceuticals, LLC.